Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...2223242526272829303132...858859»
  • ||||||||||  omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Journal:  Dynamics of the Pre-Powerstroke Myosin Lever Arm and the Effects of Omecamtiv Mecarbil. (Pubmed Central) -  Oct 16, 2024   
    Finally, we map out the distinct conformations and ligand-protein interactions adopted by OM. These results uncover some structural factors that govern the motor domain-tail orientations and the mechanisms by which OM primes the pre-powerstroke myosin heads.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Minimal residual disease:  Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) -  Oct 16, 2024   
    P4,  N=10, Terminated, 
    The resulting preservation of vascular and bone health will be assessed for the first time by examining aortic and iliac artery calcifications and vertebral fractures, respectively. N=45 --> 10 | Trial completion date: Dec 2025 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Sep 2024; The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date, Trial initiation date, Trial primary completion date:  Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia (clinicaltrials.gov) -  Oct 16, 2024   
    P3,  N=440, Not yet recruiting, 
    N=45 --> 10 | Trial completion date: Dec 2025 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Sep 2024; The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned. Trial completion date: Oct 2026 --> Oct 2027 | Initiation date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2026 --> Oct 2027
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab - protection for bone and beyond? (Pubmed Central) -  Oct 15, 2024   
    The findings guide clinicians in selecting optimal treatments and underscore the need for further research to refine evidence-based approaches, ultimately enhancing patient outcomes and quality of life. No abstract available
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Trial completion date, Trial primary completion date, Monotherapy:  CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) -  Oct 15, 2024   
    P1,  N=1200, Recruiting, 
    Conclusions Tarlatamab demonstrated durable responses and a manageable safety profile in this post hoc analysis of patients with previously treated SCLC from the Asia region. Trial completion date: Mar 2028 --> Jun 2029 | Trial primary completion date: Sep 2025 --> Jan 2027
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
    Phase classification:  AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) -  Oct 15, 2024   
    P1,  N=23, Active, not recruiting, 
    Trial completion date: Mar 2028 --> Jun 2029 | Trial primary completion date: Sep 2025 --> Jan 2027 Phase classification: P1b --> P1
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Trial completion date, Trial primary completion date:  STARS: STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS (clinicaltrials.gov) -  Oct 15, 2024   
    P3,  N=260, Recruiting, 
    Phase classification: P1b --> P1 Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
  • ||||||||||  Stivarga (regorafenib) / Bayer
    DPP4 INHIBITION AUGMENTS THE ANTI-TUMOR EFFECT OF COMBINED ANTI-PD-1 ANTIBODY/REGORAFENIB IN HEPATOCELLULAR CARCINOMA () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_2623;    
    Optimum therapy of patients for HCC after delisting needs further study. This study demonstrates that a DPP4 inhibitor augments the anti-tumor effect of the immune-based combination therapy of anti-PD-1 antibody and regorafenib by recruiting an increased proportion of effector immune cells, notably NKT cells, in the tumor microenvironment without causing hepatotoxicity.
  • ||||||||||  MASH 2B TRIALS- A SYSTEMATIC REVIEW () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_2363;    
    Lanifibranor and icosabutate showed promise, especially in T2D patients. FGF21 analogues like efruxifermin improved fibrosis, while FGF19 trials had variable results.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    CHARACTERIZATION OF LIVER INJURY INDUCED BY CDK 4/6 INHIBITORS INDUCED LIVER INJURY () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1960;    
    CDKIs, especially ribociclib, are associated with hepatocellular hepatitis in MBC treatment. Corticosteroids appear beneficial when spontaneous improvement is absent, but further data are needed
  • ||||||||||  Orkedia (evocalcet) / Mitsubishi Tanabe, Upasita (upacicalcet) / Suzuken, Pathalys Pharma, Kissei, Parsabiv (etelcalcetide) / Amgen
    Review, Journal:  New calcimimetics for secondary hyperparathyroidism in CKD G5D: do they offer advantages? (Pubmed Central) -  Oct 15, 2024   
    This agent has greater clearance by hemodialysis and shows no effect on gastric emptying. More studies are needed comparing the old calcimimetics to the new ones to establish their future role in the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) G5D.
  • ||||||||||  Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
    Journal:  Perinatal management and follow-up in a child with a prenatal diagnosis of OTC deficiency: a case report. (Pubmed Central) -  Oct 15, 2024   
    To date, after 3.5?years of follow up, growth and neurological development have been adequate, biochemical control has been appropriate except for a simple and mild decompensation during the course of a gastroenteritis. This case emphasises the importance of early diagnosis and treatment to avoid potential complications.
  • ||||||||||  zanzalintinib (XL092) / Exelixis
    P3 data, Journal, Metastases:  STELLAR-303: randomized phase III study of zanzalintinib (Pubmed Central) -  Oct 15, 2024   
    P3
    Presented is the design of STELLAR-303, a global, phase III, open-label, randomized study evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with non-MSI-H mCRC who progressed during/after or are refractory/intolerant to standard-of-care therapy. The primary end point is overall survival in patients without liver metastases.Clinical Trial Registration: NCT05425940 (ClinicalTrials.gov).
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial primary completion date:  TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset (clinicaltrials.gov) -  Oct 15, 2024   
    P1,  N=20, Recruiting, 
    Trial completion date: Apr 2028 --> Mar 2029 Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Jul 2024 --> Sep 2025
  • ||||||||||  Journal, Metabolomic study:  Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics. (Pubmed Central) -  Oct 14, 2024   
    Cells treated with a combination of subtoxic doses of trametinib and BKM120, an inhibitor of the PI3K pathway, showed a synergistic response between the two pathways...RS metabolites were verified with mass spectrometry, and enrichment pathways were identified, including amino acid, purine, and nicotinate and nicotinamide metabolism that differentiated monotherapy from combination therapy. Our approach may ultimately be applicable to patient-derived primary cells and cultures of patient tumors to predict effective drugs for individualized care.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Review, Journal:  A practical approach for anabolic treatment of bone fragility with romosozumab. (Pubmed Central) -  Oct 14, 2024   
    Our approach may ultimately be applicable to patient-derived primary cells and cultures of patient tumors to predict effective drugs for individualized care. Based on the available evidence, romosozumab could be proposed as ideal drug in several clinical settings, such as non-fractured post-menopausal women at very-high risk of fractures, patients with recent hip fracture, patients non responder to bisphosphonates and short-term denosumab therapy.
  • ||||||||||  Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ? 65 Years With Daily or Nondaily Migraine. (Pubmed Central) -  Oct 14, 2024   
    This retrospective analysis provides real-world evidence that there is no difference in the efficacy and tolerability of treatment with erenumab, fremanezumab, and galcanezumab in patients O65 when compared with patients U65 both with daily or nondaily migraine. These data may help guide the choice of migraine treatment in older populations.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Blinatumomab as a novel therapeutic approach in systemic sclerosis: a case report (Osaka/Samarkand) -  Oct 13, 2024 - Abstract #DGHO2024DGHO_1470;    
    The treatment was safe, and the patient showed a substantial clinical benefit. The treatment strategy foresaw depleting the bulk of B-cells with an initial low dose and starting the higher dose at low B cell counts, this way CRS could be prevented.
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen, Tasigna (nilotinib) / Novartis, Inhibikase
    Importance of alloHSCT in Ph+ ALL in the era of targeted and immunotherapies (Shanghai) -  Oct 13, 2024 - Abstract #DGHO2024DGHO_923;    
    A phase 2 study using hyperCVAD and ponatinib reported a CR rate of 100%, a complete molecular remission (CMR) rate of 86%, and an estimated 6-year OS of 75%...The GIMEMA group explored a chemotherapy-free approach by combining dasatinib with blinatumomab, achieving a CR rate of 98%, a CMR rate of 55%, and an OS of 80.7% at 53 months follow-up...The GRAAPH 2014 phase 3 trial highlighted a higher relapse rate with reduced-intensity chemotherapy combined with nilotinib, emphasizing the importance of consolidation chemotherapy intensity...Additionally, the duration of TKI treatment and associated side effects, along with concerns about CNS relapses, suggest that some form of chemotherapy may still be necessary. Future trials, such as the upcoming GRAAPH randomized phase 3 trial, aim to determine whether patients in CMR can forgo alloSCT.